by Raynovich Rod | Jan 14, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPM Notes #2 : Investors buy into Life science innovation After a lackluster day Monday the tape for JPM life science sector stocks picked up with a decent rally. Major ETFs reversed the trend from yesterday with the IBB up 1.64% and the XBI up 2.94% despite NASDAQ...
by Raynovich Rod | Dec 22, 2019 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-4 January 2 , 2020. 12:11 EST….. Biotechs and Healthcare lagging a bit in the New Year. Watch rotation into other sectors -tech, financial, energy; update at end of week. Many mid and small caps are weak despite NAZ up 0.66%. Russell 2000 is down 0.79%....
by Raynovich Rod | Dec 9, 2019 | Biopharmaceuticals, Macro
Update-1 …12/12/19…China Deal Announcement Boosts Dow S&P and NASDAQ. IBB up 0.68%, XBI up 0.58%, XLV up 0.93%. Large cap leaders: ABBV ALXN BMY, Chips, energy, financials strong; real estate weak. 10 year yield moves up to 1.894% =========== Early...
by Raynovich Rod | Nov 30, 2019 | Biopharmaceuticals
Update-2 …12/3…Biotech among the leading sectors on a sell-off day With NASDAQ off 0.55% and the S&P down 0.68%, biotech stocks were oblivious to the trade worries and had a huge rally driven by gene therapy stocks. The XBI was up 1.47% and most mid...
by Raynovich Rod | Nov 24, 2019 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/25/19… Rally right on track driven by NVS/MDCO deal, new product surge and cheap money from FED. As we said many time on this site XBI is the bellwether up 4.25% today (UP 13% in one month) as biotech stocks broke out last week. IBB up 2.46%. We...
by Raynovich Rod | Nov 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/20…China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on...
by Raynovich Rod | Nov 12, 2019 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2…One of the best days of the year for us; I will summarize later. Only laggard sector was speculative microcaps. Some of our best gains among healthcare/life science stocks: ABBV AMRN CRSP GILD ILMN TDOC UNH VCYT XBI ======= Update-1… Biotech gains...
by Raynovich Rod | Nov 4, 2019 | Biopharmaceuticals
Update-1 11/5 2p EST IBB flat, NAZ up 0.185, earnings from AMRN and REGN. Amarin down 3.5% to $16.83 on earnings but bulls are waiting for label expansion. Q3 Revenues are $112.4 M up 103%, increased prescriptions for Vascepa with a 12/28/19 PADUFA date. Regeneron...
by Raynovich Rod | Oct 28, 2019 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update 10/30 1:45 pm EDT Markets weak on China deal, PMI data Sold CRSP at $50.with 25% gain in 2 weeks; will get back in on weakness. XBI off 0.89%, IBB down 0.85%, NAZ off 0.44%. BMY up 1.5% near 52 week highs. Teledoc (TDOC) a top 2019 small cap pick up over 12% on...
by Raynovich Rod | Oct 23, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 10/25 at close…A Good Day on Low Volume-NASDAQ up 0.7%, S&P is up 20.56% YTD! Large caps mixed with IBB down a tad 0.29%;leaders are BIIB,BMY,RHHBY NASDAQ-100 at record high; QQQ up 0.8% to $195.64. Gilead Sciences (GILD) a big loser on earnings...
